NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

Bergen, Norway and Oslo, Norway, 30 June 2025: BerGenBio ASA the ("Company")
hereby announces a fully underwritten rights issue with preferential
subscription rights (the "Subscription Rights") for the Company's existing
shareholders at the time of completion of the proposed merger between BerGenBio
Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced
in a separate announcement earlier today (the "Merger") to raise gross proceeds
of approximately NOK 130 million, which pursuant to certain Underwriting
Agreements (as defined below) will be fully underwritten by a consortium of
underwriters comprising certain large shareholders in Oncoinvent ASA and certain
external underwriters (the "Underwriters") (the "Rights Issue"). The Rights
Issue is subject to and will be completed subsequent to the completion of the
Merger. The Merger is currently anticipated to be completed mid of September
2025 and the Rights Issue will then be implemented start/mid of October 2025.

The net proceeds from the Rights Issue and the Merger are expected to allow the
combined company to reach the following milestones:

-          Final Phase 1 ovarian data: Final data read-out from the Phase 1
trial at 24 months follow-up. The final data will include 10 patients and is
expected during H2 2025

-          Complete Phase 2 recruitment: Completion of recruitment (96 patients)
for the randomized controlled phase 2 trial in peritoneal metastases originating
from ovarian cancer (OC)

-          Interim Phase 2 data: Interim data read-out from the phase 2 trial in
OC at 9 months follow-up. The interim data will be completed at a pre-defined
time point during H2 2026 and will include data for the patients that have
reached the 9-month follow-up point at that time

-          Commencement of external manufacturing scale-up program for
Radspherin®

The net proceeds will further be used for general corporate purposes and is
expected to provide cash runway into 2027.

The proposed Rights Issue is subject to, inter alia, approval by the Company's
shareholders at an extraordinary general meeting in the Company (the "EGM"),
expected to be held on or about 4 August 2025. The notice of the extraordinary
general meeting will be published in a separate press release.

ABG Sundal Collier ASA ("ABGSC") and DNB Carnegie, a part of DNB Bank ASA ("DNB
Carnegie") have been engaged as joint lead managers and joint bookrunners (the
"Managers") for the Rights Issue.

Terms and conditions for the Rights Issue

The Rights Issue is subject to, inter alia, the following conditions (together,
the "Conditions"):

(i)                  the shareholders in each of the Company and Oncoinvent ASA
having validly approved the Merger, and the Merger having been completed